Correlation Between Mineralys Therapeutics, and HCW Biologics

Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and HCW Biologics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and HCW Biologics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mineralys Therapeutics, Common and HCW Biologics, you can compare the effects of market volatilities on Mineralys Therapeutics, and HCW Biologics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of HCW Biologics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and HCW Biologics.

Diversification Opportunities for Mineralys Therapeutics, and HCW Biologics

-0.3

Correlation Coefficient

Mineralys Therapeutics,  HCW Biologics

Very good diversification

The 3 months correlation between Mineralys and HCW is -0.3. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and HCW Biologics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on HCW Biologics and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with HCW Biologics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of HCW Biologics has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and HCW Biologics go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and HCW Biologics

Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to generate 0.42 times more return on investment than HCW Biologics. However, Mineralys Therapeutics, Common is 2.38 times less risky than HCW Biologics. It trades about 0.07 of its potential returns per unit of risk. HCW Biologics is currently generating about 0.02 per unit of risk. If you would invest  1,252  in Mineralys Therapeutics, Common on December 28, 2024 and sell it today you would earn a total of  248.00  from holding Mineralys Therapeutics, Common or generate 19.81% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Mineralys Therapeutics, Common  vs.  HCW Biologics

Mineralys Therapeutics,

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Mineralys Therapeutics, unveiled solid returns over the last few months and may actually be approaching a breakup point.

HCW Biologics

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in HCW Biologics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating basic indicators, HCW Biologics sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Mineralys Therapeutics, and HCW Biologics

The main advantage of trading using opposite Mineralys Therapeutics, and HCW Biologics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, HCW Biologics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HCW Biologics will offset losses from the drop in HCW Biologics' long position.

The idea behind Mineralys Therapeutics, Common and HCW Biologics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.